ABSTRACT Receptor-mediated uptake and degradation of 1251-asialoorosomucoid (ASOR) in human hepatoma HepG2 cells is inhibited by the lysosomotropic amines chloroquine and primaquine. In the absence of added ligand at 37°C, these amines induce a rapid (t1/2 5.5-6 min) and reversible loss of cell surface "'I-ASOR binding sites as well as a rapid decrease in 125 1-ASOR uptake and degradation . There is no effect of these amines on the binding of "'I-ASOR to the cell surface at 4°C or on the rate of internalization of prebound 125 1-ASOR . The loss of "'I-ASOR surface binding at 37°C is not attributable to altered affinity of ligandreceptor binding . In the presence of added ligand at 37°C, there is a more rapid (t1/2 2.5-3 min) loss of hepatoma cell surface receptors . In addition, the amines inhibit the rapid return of the internalized receptor to the cell surface . We examined the nature of this loss of 1251-ASOR surface binding sites by following the fate of receptor molecules after biosynthetic labeling and after cell surface iodination . At 37°C, chloroquine and primaquine induce a loss of asialoglycoprotein receptor molecules from the hepatoma cell surface to an internal pool .
The selective uptake of macromolecular ligands such as proteins via receptor-mediated endocytosis is a common feature of eucaryotic cells (1, 2) . Receptor-mediated endocytosis involves the specific binding of macromolecular ligands (e.g., virus, toxin, transferrin, asialoglycoprotein) to specialized cell surface receptors and their internalization via a coated pitcoated vesicle pathway. Many ligands dissociate from their receptor in a prelysosomal compartment and allow the receptor to recycle back to the cell surface (1, 2) . Often, these ligands are then transported in a still unknown way to the lysosomes, wherein they are degraded. The asialoglycoprotein receptor (ASGP-R),' localized to the hepatic parenchymal cell, provides a well-characterized system for examination of the mechanisms involved in these processes (3) . A human hepatocyte-derived cell line, hepatoma HepG2, contains abundant ASGP-R (4) . Using these cultured cells as a model, we have recently defined the kinetics of receptor-mediated endocytosis of asialoglycoprotein ligands and ASGP-R recycling (5, 6) . Our studies indicate that a single ASGP-R can recycle from the cell surface into "endosomal sorting compartments" (compartment of uncoupling receptor and ligand ' Abbreviations used in this paper. ASGP, asialoglycoprotein; ASGP-R, ASGP receptor; ASOR, asialoorosomucoid .
[CURL]) within the cell and back to the cell surface within 8 min (5-7).
The mechanisms responsible for ligand-receptor dissociation and the sorting and recycling of receptor molecules are not fully understood. Lysosomotropic agents (including the weak bases ammonium chloride and chloroquine) have been demonstrated to interfere with receptor-mediated uptake and degradation of numerous ligands, including asialoglycoproteins (8) , mannose-6-phosphate-terminated ligands (9) , alpha-2-macroglobulin-protease complexes (10) , mannosylated albumin (11) , and low-density lipoproteins (12) . Both lysosomes (13) and endosomes (14, 15) are now known to be acidic, and the pH of both organelles can be raised by the presence of lysosomotropic agents (16) . Studies following the fate of labeled ligand suggest that the lysosomotropic agents interfere with receptor recycling by sequestering receptor within intracellular compartments (17) .
The hepatoma ASGP-R is a well-characterized system with which to examine the effects of the lysosomotropic amines on receptor recycling, since both well-defined parameters for ASGP-R recycling (5) and anti-human ASGP-R antibodies (18) are available. In the present study we define the effects of two lysosomotropic amines on the parameters of endocytosis of asialoglycoprotein in cloned hepatoma HepG2 cells.
In the presence of the amines there is a rapid loss of cell surface binding sites . By following labeled receptor molecules, we demonstrate that the amines induce a loss of cell surface receptor to an internal pool. These data provide support for the constitutive recycling of ASGP-R in HepG2 cells.
MATERIALS AND METHODS
Materials : Human orosomucoid, provided by the American Red Cross, was desialylated and iodinated with I'll as previously described (19) . Chloroquine and primaquine were obtained from Sigma Chemical Company (St . Louis, MO) as the biphosphate salts, and monensin was obtained from Calbiochem-Behring Corp. (La Jolla, CA). All drug solutions were prepared fresh in Eagle's minimal essential medium (Gibco Laboratories, Grand Island, NY) for each experiment. The preparation and characterization ofaffinity-purified antihuman ASGP-R antibodies has been described (l8) .
Cells : The human hepatoma cell line HepG2 (clone a16) was used for all studies reported here . Maintenance of these cells has been detailed earlier (4, 18) .
Binding, Uptake, Degradation, and Internalization Assays : The binding of ' ZS I-asialoorosomucoid (ASOR) to HepG2 cells at 4°C has been described ; specific binding is defined as the difference of binding of ' ZS I-ASOR in the absence and presence of excess unlabeled ASOR (4) . Assays for the uptake and degradation of "I-ASOR at 37°C have been described (5) . However, in the present study the medium used was Eagle's minimal essential medium/ 10% fetal calf serum/ 10 mM Hepes (pH 7.3). In general, uptake was assayed during a 2-h period at 37°C, a time period during which release of`D 6I degradation products into the medium is minimal (5) . Degradation was generally assayed at 4 h at 37°C .
Internalization was assessed by evaluating the cell-associated, EDTA-nonreleasable "'I-ASOR within cells (5) . Cells were exposed to "I-ASOR at 4°C in order to saturate all surface receptors . Unbound "'I-ASOR was removed and the cells were temperature-shifted to 37°C for various times and then returned to 4°C. The cells were then treated for 5 min at 4°C with 10 mM EDTA in PBS (pH 5). Both the I 'l l-ASOR released by this treatment (cell surface ligand) and that sequestered within the cells (EDTA-nonreleasable) were determined (5) .
Biosynthetic Labeling of Receptor : Biosynthetic labeling of human ASGP-R was performed using ["S]methionine as detailed previously (l8). Cells were labeled with 300 gCi of [SS S]methionine/ml for 60 min followed by a 2-h chase period in the presence of 400-fold excess unlabeled methionine .
Immunoprecipitation of ASGP-R and Analysis by SDS PAGE: After biosynthetic labeling and exposure to drugs, the cells were chilled to 4°C. For the analysis of total cell receptor, cells were solubilized in I% Triton X-100/1 mM phenylmethylsulfonyl fluoride in PBS and immunoprecipitated with affinity-purified anti-human ASGP-R antibody as described previously (18) . Immune complexes were isolated with Staphylococcal protein A, and the antigens and antibodies were separated by SDS-PAGE and prepared for fluorography with Enhance (New England Nuclear, Boston, MA) (18) . Densitometry was performed using a Helena Laboratories (Beaumont, TX) Quickscan with integrator.
Immunoprecipitation of ASGP-R from the Cell Surface : As described previously (l8), after the appropriate biosynthetic labeling, cells were chilled at 4°C, washed in PBS containing PMSF, and incubated for 3 h at 4°C with affinity-purified anti-human ASGP-R (5-60 gg/ml in PBS/l mM PMSF containing 0 .1 mg/ml cytochrome c). Following removal of the unbound IgG, the cells were solubilized in 1% Triton X-100/1 mM phenylmethylsulfonyl fluoride/PBS containing a l0-fold excess of unlabeled cell extract (to prevent surface IgG from binding intracellular labeled receptor, which became available during solubilization) . This material was subjected to immunoprecipitation and analysis by SDS PAGE and fluorography (18) .
Cell Surface Iodination : HepG2 cells were vectorally labeled with 'ZSI at 4°C as previously described (20) . Briefly, 106 cells were washed with PBS and incubated for 15 min at 4°C with 1 mCi 'ZSI in the presence of lactoperoxidase and glucose oxidase. The cells were then washed, solubilized in 1 % Triton X-100/1 mM phenylmethylsulfonyl fluoride/PBS, immunoprecipitated, and analyzed on SDS PAGE.
RESULTS
In the absence of added ligand, chloroquine (1 mM) induces a rapid loss ofhepatoma "'I-ASOR surface binding. At 37°C, the half-time for depletion of surface binding sites is 5-6 min (Fig. 1) . The effect is similar to the decrease of surface ligand binding of ASGP on isolated rat hepatocytes (8) and mannosylated BSA binding on alveolar macrophages (11) . Identical kinetics ofloss ofASGP surface binding was found with (0.2-1 mM) primaquine (data not presented). Chloroquine (20-200 AM) had minimal effects on the extent of "'I-ASOR surface binding during a 2 .5-h incubation at 4°C (Fig. 2 a) . However, there was a dose-dependent loss of surface binding in cells exposed to the drug at 37°C, which resulted in a 50% inhibition (I5o) at -100 AM; the No was -400 AM (Fig. 2 a) . Similarly, primaquine had little if any effect on the saturation binding of 'ZS I-ASOR during incubation at 4°C. Primaquine also produced a dramatic effect at 37°C with an 150 of -70 AM and an I9o of 200 AM (Fig. 2a) . Other primary amines, e.g., ammonium chloride and methylamine, were found to have similar but less potent effects (Table I ). The carboxylic cationic ionophore monensin similarly decreased "'I-ASOR binding to hepatoma cells (Table I) .
We also examined the effect of these drugs on the uptake of ' ZS I-ASOR into hepatoma cells. We chose a period of 2 h at 37°C, a time by which little internalized ligand has been released into the media as degradation products (5) . As seen in Fig. 2 b, both chloroquine and primaquine induced a drugdependent reduction of ' ZS I-ASOR uptake (I50 -80 uM; I9o -200 AM) . Similar to the effects on surface binding and uptake at 2 h, ' Z SI-ASOR degradation, assessed after 4 h at 37°C, was inhibited by both chloroquine and primaquine in a dose-dependent manner (150 -40-50 AM for chloroquine and 70 AM for primaquine; I9o 100 AM for chloroquine and 200 AM for primaquine) (Fig. 2e) . Furthermore, identical effects of inhibition of uptake and degradation were seen in samples examined after 20 h ofligand uptake and degradation (data not presented). In addition, similar effects were seen after exposure to ammonium chloride, methylamine, and monensin (Table I) .
Internalization ofsurface-bound`ZS I-ASOR was unaffected by 200 AM primaquine or chloroquine (Fig. 3) . The t Z of2-2.2 min is identical to that reported earlier (5) . However, the extent of internalization of surface-bound 'ZSI-ASOR may be reduced by 10% at longer incubation times (e.g., 10 min) ( This inhibitory effect of chloroquine and primaquine on the uptake of 'ZSI-ASOR in hepatoma cells is rapidly reversible . As seen in Table II , the removal of 200 AM primaquine from the media after a 30-min preincubation at 37°C allowed the uptake of 121 I-ASOR to return to control values (94%) by 2 h at 37°C, while cells maintained with 200 ,M primaquine at 37°C demonstrated only 8% control uptake . Furthermore, replacement of primaquine with chloroquine at equimolar concentrations during the uptake incubation demonstrated that chloroquine was not as effective in maintaining the inhibition of "'I-ASOR uptake, which is consistent with the effects on surface binding and uptake seen in Fig. 2 .
Since chloroquine and primaquine promote a loss ofsurface ligand binding sites, in addition to reducing ligand degradation (Fig. 2) , we examined which effect is observed first at lower drug concentrations . In order to test this, cells were incubated with various concentrations of primaquine (20-200 AM) for 2 or 4 h at 37°C. Thereafter, we determined binding (at 4°C), degraded ligand in media, total cell-associated ligand, and internalized ligand. A dose-dependent decrease in surface ligand binding and ligand degradation at 4 h was found (Table III) and was similar to that found earlier (Fig. 2) . It should be noted that the determination of surface ligand binding is a static measurement and reflects only the number of binding sites at the cell surface at the time ofassay, in this instance after a 4-h incubation at 37°C with primaquine . In contrast, the total cell-associated ' ZSI-ASOR and degradation reflect the overall uptake and processing ofligand during 4 h. The total amount ofligand internalized decreased only slightly to 93% of control in the presence of 40 AM primaquine and to 83% of control in the presence of 70 AM primaquine (Table III) . Even at 100 AM primaquine, <30% reduction in total ligand processed was found. However, at primaquine concentrations of 20-70 pM, there was a substan- 30 min with various concentrations of primaquine . Thereafter, in the continued presence of the primaquine, saturation binding of "'I-ASOR at 4°C or uptake (total cell-associated) and degradation of "'I-ASOR at 4 h, 37°C, was assessed as described in the text . Each value is the mean of triplicate determinations with a range ±10% . * Internal = (total cell-associated -surface bound) . ' The numbers in parentheses are normalized such that 0 M primaquine equals 1 .00 .
tial increase in internal ligand (150% control) (Table III) .
Additional studies performed at 20 h demonstrated a similar increase (150% control) in internal 121I-ASOR in the presence of 60 MM primaquine (data not presented). These studies demonstrate an accumulation of undegraded ligand and suggest that the major effect of these agents is on inhibition of ligand degradation . We could directly assess the mechanism(s) responsible for the loss of ' 21I-ASOR surface binding . Hepatoma cells were incubated at 37*C with chloroquine or primaquine in order to reduce surface binding to -30% ofthe control value. Under these conditions the affinity (Kd) of "'I-ASOR binding was unaltered (data not presented). These data suggest that the loss ofsurface binding was not the result of altered affinity of receptor-ligand binding.
To examine directly whether the loss ofcell surface binding of ASOR was the result of inactivation of surface ASGP-R (i.e., it was no longer capable of binding ligand) or whether surface ASGP-R were no longer present at the cell surface, we assessed the effect of the drugs by two independent methods : immunoprecipitation of cell surface receptors after biosynthetic labeling and immunoprecipitation of total cell receptors after cell surface iodination. HepG2 cells were labeled with ["S]methionine by incubation for 60 min, followed by a 2-h chase with unlabeled methionine. These conditions allow the newly labeled receptor molecules to reach the cell surface (18) . The cells were then treated for 30 min at 37°C with 200 /AM chloroquine or primaquine. In one set ofdishes, the total receptor from the entire cell lysate was immunoprecipitated with anti-receptor antibody. As seen in Fig. 4 a, there was no difference in the amount of total cell receptor immunoprecipitated by anti-human ASGP-R antibody in the drugtreated or control cells. Approximately 95% of the labeled receptor migrated at an apparent molecular weight of 46,000, which is the molecular weight ofthe mature receptor, whereas <5% of the labeled receptor was of an apparent molecular weight of 40,000, the predominant intracellular precursor (18) . After only the surface receptor was immunoprecipitated, as seen in Fig. 4b, a level) or 200 AM primaquine (~10-15% control level) . As expected, there was no surface receptor of 40,000 mol wt . Immunoprecipitation of surface receptors allows a quantitative determination of receptor at the cell surface . As seen in Fig . 5 , after primaquine incubation there is a decrease in immunoprecipitable surface receptor that parallels the loss of ligand binding sites (Fig. 2) . This is seen at anti-receptor antibody concentrations of 5-60 Ag/ml (Kd 20-30 Ag/ml) (Figs. 4 b and 5 ; unpublished data) . An independent assessment of the presence of surface receptor after incubation with primaquine is seen in Fig . 6 . After preincubation in the absence or presence of 200 AM primaquine for 30 min at 37°C, cell surface proteins were labeled with 121 1 at 4°C. Analysis of total cell receptor after immunoprecipitation reveals a single receptor species at 46,000 mol wt in the control cells, while cells preincubated with primaquine display a dramatic reduction in the 46,000-mol wt receptor (Fig. 6) .
In HepG2 cells there is a marked ligand-induced depletion of cell surface receptors (6) . In the presence of ASGP, there is a rapid depletion of surface ASGP-R . This is followed by a rapid reappearance of surface receptors that originate for the most part from the pool of surface receptors that had internalized and recycled (6) . Therefore, we examined the effect of chloroquine and primaquine on this ligand-induced recycling of the ASGP-R. As seen in Fig. 7 , in the presence of ASOR at 37°C there is a very rapid loss (t 2 2.5-3 min) of cell surface binding in the presence of chloroquine . This initial rate (first 2 min) of loss of surface binding is unaltered by the 73 6 THE JOURNAL OF CELL BIOLOGY " VOLUME 98, 1984 presence of the amine (Fig. 7) . However, the rapid return of surface binding to control levels is abrogated by the presence of amine (Fig. 7) , i .e., there is a continued rapid loss of cell surface ASGP-R in the presence of amine . The loss of surface binding in the presence of amine and ligand is more rapid than that seen in the presence of amine alone (Figs . 1 and 7) .
DISCUSSION
The lysosomotropic agents chloroquine and primaquine inhibit receptor-mediated endocytosis of ASGPs in human hepatoma HepG2 cells . In studies performed in the absence of added ASGP, there is a dose-dependent and reversible loss of cell surface ligand binding sites, ligand uptake, and degradation. However, there is no effect of these agents on binding of ligand to surface receptor or on internalization of surfacebound ligand . These observations are consistent with earlier studies on the effects of lysosomotropic agents on the receptormediated endocytosis of ASGPs in isolated rat hepatocytes (8, 21) , as well as lysosomal enzymes, mannosyl-terminated proteins, low-density lipoproteins, alpha-2-macroglobulinprotease complexes, chorionic gonadotropin, and insulin in a variety of cell types (9-12, 17, 22-24) .
The concentrations of chloroquine and primaquine used for the most part in the present study are similar to those required to achieve significant reduction in receptormediated endocytosis of many ligands (e.g ., low-density lipoprotein [LDL], mannosyl-terminated albumin, alpha-2-macroglobulin-protease) (10) (11) (12) .
The mechanism of action of the lysosomotropic agents has been the subject of intensive investigation . This class of drugs inhibits lysosomal cathepsins and protein degradation (25, 26) , neutralizes lysosomal pH (13, 27) , and neutralizes endosomal pH (14, 16) . Many of the actions of these agents may be directly attributable to protonation within acidic intracellular compartments (27) .
Intracellular accumulation of ligand was found at intermediate concentrations of primaquine (20-70,uM) , concentrations at which ligand degradation was reduced by 75%, while surface binding was reduced only 40% (Table III) gest that at least two processes are involved in inhibition of receptor-mediated uptake and degradation by primaquine. The effect of these agents on the lysosomal degradation of ligands appears to be the more sensitive process, while loss of cell surface binding occurs at higher drug concentrations . It is presently unclear whether neutralization of lysosomal pH alone is sufficient to account for the reduction in ligand degradation observed with these agents.
The loss of cell surface binding sites seen in the presence of chloroquine or primaquine and in the absence of ligand may have resulted from (a) altered affinity of ligand-receptor binding, (b) inactivation (i.e., loss of binding activity) of receptor while still at the cell surface, or (c) loss of the receptor from the cell surface . The first possibility appears unlikely since there was no apparent alteration in receptor Kd . The latter two possibilities were examined directly using receptor-labeling (both cell surface'"-iodination and biosynthetic labeling) and anti-receptor antibodies . It was found that in the presence of chloroquine or primaquine there was a loss of ASGP-R from the cell surface, while the total cell ASGP-R was unaltered (Figs . 4-6) . Thus, surface receptor is sequestered within the cell . The intracellular site of receptor sequestration is not presently known ; however, the availability of antireceptor antibodies and colloidal gold immunocyto-electron microscopy (7) will allow this question to be directly examined.
These results are not fully consistent with the findings of Fiete et al . (28) . These authors were unable to demonstrate a loss of ASGP-R from the cell surface after treatment with monensin, although ligand binding activity decreased. However, the loss of ASGP-R from the cell surface of hepatoma cells in the presence of lysosomotropic agents is similar to that observed by Harford et al . (29) in rat hepatocytes treated with monensin. They demonstrated intracellular (endosomal) accumulation of ligand binding sites coincident with loss of ASGP-R from the cell surface .
The notion that constitutive recycling of the ASGP-R occurs in hepatoma cells is supported by two observations . First, in the absence of ligand the lysosomotropic amines induce a loss of surface receptor into an internal pool . Second, the kinetics of surface receptor loss are rapid both in the absence and in the presence of ligand. These studies suggest that the constitutive rate of ASGP-R recycling may be -35-50%Q112 5.5-6 min vs. 2.5-3 min) that seen in the presence of ligand (Fig. 7) . However, it is not known whether in the absence of ligand these agents induce receptor loss by increasing the rate of unoccupied receptor internalization or by decreasing the rate of receptor return to the surface or both. Nonetheless, the presence of ligand itself induces a rapid and transient loss of surface ASGP-R in hepatoma HepG2 cells (Fig. 7) (6) . The presence of lysosomotropic amines has no effect on the very rapid ligand-induced loss of surface receptors, but it inhibits the rapid return ofreceptors to the cell surface (Fig. 7 ). These findings demonstrate that endocytosis of the ASGP-R itself is not altered by the amines, but that these agents diminish or prevent the reappearance of internalized receptors .
Thus, it appears that the lysosomotropic agents' effect on ASGP-R recycling most likely involves a substantial decrease in the rate of receptor return from an intracellular pool. Similarly, Ciechanover et al. (30) have recently demonstrated that ammonium chloride decreases the rate of return to the cell surface of transferrin and the transferrin receptor in HepG2 cells.
The concept of constitutive recycling of receptors involved in receptor-mediated endocytosis has evolved from the studies ofTolleshaug and Berg (8), Kaplan and Keogh (10), Tietze et al. (17) , and Brown et al. (31) . In general, these studies have used various agents, including the amines and carboxylic ionophores, to demonstrate loss ofsurface ligand binding sites in the absence of ligand. In addition, Brown et al. (31) provided evidence for the intracellular trapping of LDL receptors in studies with anti-LDL receptor antibody and immunofluorescence . The present studies with the ASGP-R support these observations and provide evidence that the amines interrupt constitutive receptor recycling by diminishing the rate ofreappearance ofinternalized receptor. Although the mechanism responsible for this observation is not known, acidification within endosomal compartments (16, 32) may be obligatory for receptor reappearance at the cell surface .
